Citations

Clear

629 citation(s) found for "Zheng, Yi".

Advances in Semantic Web
Holford, Matthew, Cheung, Kei‐Hoi, Zheng, Mingna, King, T. A. , Krauthammer, Michael O. , Chute, Christopher G.

Mayo Clinic

No container title available | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.4236/9781618962648 Get It

<p class="MsoNormal"> <span lang="EN-US">The Semantic Web has the ultimate goal of making a machine understand Internet data. To enable the encoding of semantics with the data, well-known technologies are used such as RDF (Resource Description Framework) and OWL (Web Ontology Language). These technologies formally represent the meaning involved in information. For example, ontology can describe concepts, relationships between things, and categories of things. These embedded semantics offer significant advantages such as reasoning over data and dealing with heterogeneous data sources.<o:p></o:p></span> </p>
Abstract B024: Cisplatin primes an interferon-driven CD8+ central memory T cell program to enable oncolytic virotherapy in gastrointestinal cancer malignancies
Parker, Joseph Brandon., Dong, Zhongyi , Liu, Tao, Guo, Qisen , Zhang, Haoyu, Ni, Bo, Bai, Long, Chen, Yiwen, Zong, Jiasheng, Xia, Xiang, Zheng, Jiaojiao, Pham, Hoang Tran , Elalfy, Aya, Ingram, Demarcus, Abdel-Hakeem, Ahmed, Ali, Muhammad, Zhang, Z L , Yang, Vivienne , Parker, Jefferson , Liu, Tao, Ni, Bo , Bai, Long, Xia, Xiang, Pham, Hoang Tran, Elalfy, Aya, Ali, Muhammad, Hartzell, Shannon

Mayo Clinic

Clinical Cancer Research | July 21, 2026 | Volume: 32 | Issue: 14_Supplement | Pages: B024-B024

10.1158/1557-3265.d32026-b024 Get It

Abstract Background: The limited efficacy of oncolytic virotherapy (OV) in gastrointestinal malignancies has been attributed to an immunologically inert tumor microenvironment. While cisplatin is widely used as a cytotoxic agent, its immunomodulatory effects remain incompletely defined. We hypothesized that cisplatin may reprogram the tumor immune landscape to enable more effective OV-mediated anti-tumor responses. Methods: We evaluated the effects of cisplatin in combination with two distinct oncolytic platforms, vesicular stomatitis virus (VSV) and adenovirus (AdV), across both in vitro and in vivo colorectal cancer models. In vivo efficacy was assessed using MC38 subcutaneous and peritoneal metastatic models, with analysis of tumor growth, survival, and toxicity. Immune profiling was performed using single-cell RNA sequencing (scRNA-seq), flow cytometry, and bulk RNA sequencing to interrogate changes in CD8+ T cell states and functional programs. Guided by these preclinical findings, a clinical trial combining XELOX, PD-1 blockade, and OV therapy was initiated (ChiCTR2500107607). Results: Cisplatin markedly enhanced OV-mediated anti-tumor efficacy across models, resulting in sustained tumor control and improved survival in both subcutaneous and peritoneal disease settings. This effect was conserved across viral platforms, indicating a virus-agnostic interaction. Mechanistically, cisplatin induced a robust interferon (IFN)–dominant transcriptional program, characterized by upregulation of interferon-stimulated genes, including IRF7, IRF9, and ISG15. Single-cell analysis revealed that combination therapy reshaped the CD8+ T cell compartment, promoting the expansion of a population with transcriptional and functional features of central memory T cells (Tcm), alongside reduced exhaustion signatures. These changes were accompanied by enhanced cytokine signaling pathways associated with T cell maintenance and function, including IL-2, IL-7, and IL-15. In vitro, the combination of cisplatin and OV increased tumor cell death and interferon-γ production, supporting a model in which cytotoxic and immunostimulatory effects are mechanistically linked. A phase I clinical trial has been initiated. In gastric cancer, patients with retroperitoneal metastases are being treated with OV in combination with PD-1 blockade (ongoing). In colorectal cancer, the strategy is being evaluated in the neoadjuvant setting with an rectal preservation approach. Conclusions: Our findings identify a previously unrecognized role for cisplatin in priming an interferon-driven immune program that promotes Tcm differentiation and function, thereby enabling durable responses to oncolytic virotherapy. This work provides a mechanistic rationale for leveraging chemotherapy-induced immune reprogramming to enhance viro-immunotherapy and supports the clinical translation of this strategy in gastrointestinal malignancies. Citation Format: Joseph Brandon. Parker, Zhongyi Dong, Tao Liu, Qisen Guo, Haoyu Zhang, Bo Ni, Long Bai, Yiwen Chen, Jiasheng Zong, Xiang Xia, Jiaojiao Zheng, Hoang Tran Pham, Aya Elalfy, Demarcus Ingram, Ahmed Abdel-Hakeem, Muhammad Ali, Shannon Hartzell, Zizhen Zhang, Vivienne Yang. Cisplatin primes an interferon-driven CD8+ central memory T cell program to enable oncolytic virotherapy in gastrointestinal cancer malignancies [abstract]. In: Proceedings of AACR Drug Discovery and Development (AACR D3) Conference; 2026 Jul 21-24; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(14_Suppl):Abstract nr B024.
Reproducibility of 3.0 T single-frequency cardiac MR elastography for quantification of left ventricular myocardial stiffness
Cheng, Yong, Jiang, Yewen, Zheng, Z. M. , Li, Zhanglei, Wang, Zi , An, Shutian, Chen, Jun, Glaser, Kevin J. , Arani, Arvin, Yu, Y Y, Zhao, Ren, Li, Xiaohu, MD, PhD, Wang, Jun , Wang, Zhen , Glaser, Kevin J , Yu, Yongqiang , Cheng, Yong , Zheng, Zijun, Arani, Arvin , Zhao, Ren

Mayo Clinic

Radiology Advances | July 16, 2026 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/radadv/umag032 | PMID 42565103 Get It

Abstract Background Cardiac magnetic resonance elastography (MRE) allows the non-invasive quantification of myocardial stiffness, but long-interval reproducibility data at 3.0 T single-frequency 140-Hz remain limited. Purpose To evaluate the short- and long-interval reproducibility of 3.0 T cardiac MRE for left ventricular (LV) myocardial stiffness across healthy volunteers and patients with conditions associated with elevated myocardial stiffness. Materials and Methods This prospective single-center study included 69 participants: 60 healthy volunteers and 9 with cardiovascular disease (6 with aortic stenosis and 3 with long-standing hypertension). All participants underwent baseline cardiac MRE (scanner: Signa Premier 3.0 T, GE Healthcare, driver: Resoundant), an immediate short-interval rescan (SIR) within 5 minutes, and a long-interval rescan (LIR) after approximately 1 month. Left ventricular myocardial stiffness and octahedral shear strain signal-to-noise ratio were measured independently by 2 readers. Reproducibility was assessed using Bland-Altman analysis, intraclass correlation coefficients (ICCs), within-subject coefficient of variation, standard error of measurement, and smallest detectable change at the 95% confidence (SDC95) level. Results Baseline LV myocardial stiffness was higher in the disease group than in healthy volunteers, 11.73 ± 1.01 kPa and 7.80 ± 0.70 kPa (mean ± SD; P &lt; .001), respectively. Inter-reader agreement was excellent across all timepoints, with ICCs of 0.970 at baseline (95% CI, 0.953-0.982), 0.966 for SIR (95% CI, 0.945-0.979), and 0.962 for LIR (95% CI, 0.939-0.976). Within-reader scan-rescan reproducibility was also excellent. For Reader 1, stiffness ICC was 0.979 for the SIR (95% CI, 0.966-0.987) and 0.957 for the LIR (95% CI, 0.932-0.973), with SDC95 values of 0.616 kPa (95% CI, 0.528-0.741) and 0.869 kPa (95% CI, 0.744-1.044), respectively. Reader 2 showed excellent reproducibility, with ICCs ≤0.943. Conclusions 3D single-frequency 140-Hz cardiac MRE at 3.0 T provides excellent short- and long-interval reproducibility for LV myocardial stiffness quantification. The SDC95 values may help distinguish true longitudinal stiffness changes from measurement variability.
PRANA: A Deep Learning Method for Adapting Polygenic Risk Scores to Diverse Ethnic Groups
Levi, Hagai, Wang, Qin, Bolla, Manjeet K. , Dennis, Joe, Andrulis, Irene L., Antonenkova, Natalia, Au, Chun Hang, Freeman, Laura E. Beane, Bermisheva, Marina, Bodelon, Clara, Bojesen, Stig E., Brenner, Hermann, Brock, Ian W., Brüning, Thomas, Byers, Helen, Camp, Nicola J., Castelao, Jose E., Choi, Ji-Yeob, Chung, Wendy K., Collaborators, NBCS, Colonna, Sarah, Couch, Fergus J., Daly, Mary B., Devilee, Peter, Dörk, Thilo, Eliassen, A. Heather, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Faw, Kierstin, García-Closas, Montserrat, Haiman, Christopher A., Hamann, Ute, Hartman, Mikael, Hooning, Maartje J., Hoppe, Reiner , Howell, Sacha J., Investigators, ABCTB, Investigators, SGBCC, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Jernström, Helena, Joseph, Vijai, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kiprijanovska, Sanja , Koutros, Stella, Kristensen, Vessela N., Kurian, Allison W., Kwong, Ava, Lambrechts, Diether, Larson, Nicole L. , Marchand, Loic Le, Li, Shuai, Li, Jingmei, Lophatananon, Artitaya, Mannermaa, Arto, Matsuo, Keitaro, Maxwell, Whitney, Muir, Kenneth, Nevelsteen, Ines, Obi, Nadia, O’Brien, Katie M., Ofit, Kenneth, Ottewell, Penelope D., Patel, Alpa V., Plaseska-Karanfilska, Dijana, Prajzendanc, Karolina , Ramachandran, Dhanya, Rashid, Muhammad U., Saloustros, Emmanouil, Sandler, Dale P., Schöttker, Ben, Simard, Jacques, Southey, Melissa C., Stone, Jennifer, Teras, Lauren R., Truong, Thérèse, Weinberg, Clarice R., Yamaji, Taiki , Zheng, Wei, Easton, Douglas F., Elkon, Ran , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W. , Li, Shuai , Lambrechts, Diether , Lambrechts, Diether , Kurian, Allison W , Li, Shuai , Levi, Hagai , Au, Chun , Augustinsson, Annelie , Freeman, Laura E. Beane , Behrens, Sabine , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Brenner, Hermann , Brock, Ian W., Brüning, Thomas , Byers, Helen, Camp, Nicola J. , Castelao, Jose E. , Choi, Ji-Yeob , Chung, Wendy K. , Colonna, Sarah V. , Couch, Fergus J. , Czene, Kamila , Daly, Mary B., Devilee, Peter , Dörk, Thilo, Evans, D. Gareth , Fasching, Peter A., Faw, Kierstin, Gago-Domínguez, Manuela , García‐Closas, Montserrat , Haiman, Christopher A. , Hartman, Mikael , Ho, Vikki , Ho, Peh Joo , Hooning, Maartje J. , Investigators, S On Behalf Of The Chlovis Study, Iwasaki, Motoki , Jakubowska, Anna, Jernström, Helena , Joseph, Vijai, Kaaks, Rudolf , Хуснутдинова, Э. К. , Koutros, Stella , Kristensen, Vessela N., Kwong, Ava , Marchand, Loı̈c Le , Li, Jingmei, Lophatananon, Artitaya , Mannermaa, Arto , Nevelsteen, Ines , Obi, Nadia , O’Brien, Katie M. , Ottewell, Penelope Dawn , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Radice, Paolo , Ramachandran, Dhanya , Romero, Atocha , Saloustros, Emmanouil , Sandler, Dale P. , Schöttker, Ben , Simard, Jacques , Southey, Melissa C. , Sugier, Pierre‐Emmanuel , Taylor, Jack A. , Teras, Lauren R. , Truong, Thérèse , Weinberg, Clarice R. , Yadav, Siddhartha , Dunning, Alison M. , Mavaddat, Nasim , Easton, Douglas F. , Michailidou, Kyriaki , Shamir, Ron

Mayo Clinic

No container title available | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.12.26357860 | PMID 42523604 Get It

Abstract Polygenic risk scores (PRSs), which quantify inherited susceptibility to complex traits and diseases, have emerged as valuable tools for risk stratification and precision medicine. Despite their promise, PRS developed on European cohorts often demonstrate substantially reduced predictive accuracy in non-European populations, due to differences in genetic architecture. The disproportionate representation of European ancestry cohorts in genome-wide association studies (GWAS) leads to inequitable deployment of PRS technologies across diverse populations. Here, we introduce PRANA (Polygenic Risk Adaptation via Neural-network Architecture), a deep learning framework that adapts an existing PRS developed on one population to other ancestries. Unlike methods that require large-scale GWAS in the target population, PRANA leverages pre-trained PRS models derived from European cohorts and adapts them using modestly sized cohorts from the target population. We evaluated PRANA on seven complex traits in South Asian, East Asian and Ashkenazi Jewish populations, as well as in selected smaller East Asian subpopulations where the scarcity of training data poses a particular challenge. PRANA mostly improved predictive performance of the baseline PRS models by 5%-20% in terms of effect size (β) and Nagelkerke’s R², and, in most cases, outperformed existing cross-ancestry multi-PRS approaches. These results highlight PRANA as a scalable and practical strategy to reduce disparities in genomic risk prediction and advance the equitable application of PRS in diverse populations.
Towards Automated Quality Assurance: Integrating Deep Learning and Classical ML into the Digital Radiography Pipeline
Chen, Hsuan‐Yu , Chou, Cheng‐Fu , Liao, Sheng-Hung, Wu, Mia , Chen, Kuan-Yi, Yang, Ta-Wei , Chang, Chih‐Hao , Fan, Jungwei Wilfred, Chang, Chih-Hao , Fan, Jungwei

Mayo Clinic

Diagnostics | July 6, 2026 | Volume: 16 | Issue: 13 | Pages: 2111

10.3390/diagnostics16132111 | PMID 42449892 Get It

Background/Objectives: To develop and evaluate a deep learning-based quality control system for Lumbar Spinal Digital Radiographs (LSDR), designed to automate and improve their evaluation and reduce reliance on manual reviews. Methods: This retrospective study utilized a deep learning workflow comprising image segmentation, feature extraction, and a classification model. The dataset, including anteroposterior (AP) and lateral (LAT) X-ray images, was expanded through data augmentation techniques. Four U-Net-based models were assessed: standard U-Net, Swin-UNet, Attention U-Net, and Attention U-Net with the weight map, with the latter selected for its superior performance. Extracted features, such as brightness, contrast, and anatomical positioning, were used in an XGBoost classifier, which was evaluated using mean intersection over union (mIoU), accuracy, sensitivity, specificity, and AUC. Results: The Attention U-Net with weighted attention outperformed the other models, achieving high mIoU scores in both AP and LAT views. The XGBoost classifier achieved the best performance in classifying images as “qualified” or “unqualified,” with an AUC of approximately 0.9, high accuracy, and balanced sensitivity and specificity. This approach effectively addressed class imbalances and improved model accuracy compared to traditional machine learning models such as MLP and SVM. Conclusions: The developed automated quality control system demonstrated potential for enhancing image quality, enhancing diagnostic reliability, and optimizing clinical workflow efficiency.
Procedure Training Workshop: Enhancing Resident Experience and Enthusiasm for Ultrasound-guided Bedside Procedures
Zheng, Cynthia , Abubeker, Ibrahim Y. , Freeman, Sarah , Freeman, Sarah R

Mayo Clinic

Journal of Brown Hospital Medicine | July 1, 2026 | Volume: 5 | Issue: 3 | Pages: No page available

10.56305/001c.162045 | PMID 42405368 Get It

Background Accreditation Council for Graduate Medical Education (ACGME) requires internal medicine (IM) residents to perform procedures considered “essential for the area of practice.” However, no guidelines or best practices exist for teaching these skills. To address this gap, a procedure training workshop (PTW) was developed. Methods IM residents attended a PTW where they practiced paracenteses, lumbar punctures (LPs), and central venous catheter (CVC) placement on ultrasound-compatible task trainers. The PTW was assessed using pre- and post-session tests and surveys. To evaluate translation into clinical practice, procedure volume, success rates, and immediate complications were tracked. Results Following implementation of the PTW, resident knowledge assessment scores increased from 67.4% to 84.1% (p < 0.001). More residents reported feeling “well-prepared” to perform or “teach others” procedures (CVC 69% from 31%, p < 0.01; LP 71% from 8%, p < 0.05; paracentesis 80% from 28%, p < 0.05) and able to perform all steps without assistance or model (CVC 54% from 28%; LP 49% from 17%, p < 0.01; paracentesis 66% from 25%, p < 0.01). Paracenteses increased from 71 (2020) to 119 (2021) to 143 (2024), while LPs increased from 87 (2020) to 156 (2021) to 135 (2024). Success rates remained stable across procedures: paracentesis (91.5% to 94.1% to 93.7%), LP (58.6% to 55.8% to 52.6%), and CVC placement (95.5% to 97.6% to 94.9%). Conclusions PTW is a valuable half-day session that equips early residents with essential procedural knowledge and hands-on practice that translates into sustained increases in bedside procedure volume.
Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis
Kueh, Martin T. W., Yeo, J Q, Chen, Yuehua , Chua, Nicole Ying Zi, Koh, Hui Lian , Khaw, Seng Pei , Jabbar, Hassan, Wang, Jiong‐Wei , Lee, Kwan , Sun, Dan Qin, Mantovani, Alessandro, Chew, Nicholas WS, Zheng, Ming‐Hua , Targher, Giovanni , Zhou, Xiao-Dong , Zheng, Ming-Hua , Lee, Kwan S , Kueh, Martin Tze Wah , Chen, Yiming , Chin, Yip Han , Mantovani, Alessandro

Mayo Clinic

Liver International | June 25, 2026 | Volume: 46 | Issue: 7 | Pages: No page available

10.1111/liv.70747 | PMID 42347761 Get It

ABSTRACT Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is highly prevalent and increasingly recognized as a multisystem cardiometabolic disorder. The global burden, incidence and prognostic implications of coexisting chronic kidney disease (CKD) in MASLD remain uncertain. Methods In this meta‐analysis, we searched MEDLINE and EMBASE from inception through September 25, 2025, for observational studies reporting CKD prevalence and/or incidence among adults (≥ 18 years) with MASLD. The primary outcomes were pooled CKD prevalence, estimated using random‐effects models on the logit scale with the Hartung–Knapp adjustment, and pooled CKD incidence (per 1000 person‐years), estimated using random‐effects models with exact Poisson confidence intervals. Secondary outcomes included all‐cause mortality and cardiovascular, renal and cancer outcomes. Results From 2811 records, 36 observational studies met the inclusion criteria. Twenty‐three studies contributed prevalence estimates (575 615 participants; 56 248 CKD cases) and thirteen studies contributed incidence estimates (27 996 new events). The pooled global CKD prevalence among individuals with MASLD was 15.22% (95% CI 9.69–23.12). The pooled CKD incidence was 22.17 per 1000 person‐years (95% CI 11.44–32.89) in the MASLD population. Hypertension (OR 1.49, 95% CI 1.29–1.72), dyslipidaemia (OR 1.22, 95% CI 1.20–1.24) and diabetes (OR 1.94, 95% CI 1.69–2.22) were associated with higher odds of CKD in the MASLD population. All‐cause mortality rates were 18.28 per 1000 person‐years (95% CI 3.45–33.11) in coexistent MASLD and CKD, more than double those in the MASLD‐only population (7.26 per 1000 person‐years (95% CI 2.97–11.56)). Conclusions Coexistent CKD affects one in seven individuals with MASLD worldwide, conferring a more than two‐fold increased risk of all‐cause mortality compared with individuals with MASLD alone.
An Integrated muti-omics cell atlas of the human trabecular meshwork and ciliary body
Jian, Jinjing , Bao, Xuan , Zheng, Y , Shao, Jianming , Yang, Tingting , Yaman, Ismail, Li, Jean , Chen, Han, Tolman, Nicholas, Sheridan, Carl, Zode, Gulab S., John, Simon W. M. , Stout, J Timothy, Stamer, Dan, Li, Yumei, Li, Jin , Shao, Jianming , Liu, Yutao , John, Simon Wm , Chen, Rui , Wang, Yi-Xiang , Tolman, Nicholas G. , Scheuermann, Richard H. , Zheng, Jie , Sheridan, Carl , Liu, Yutao , Du, Yiqin , Balasubramanian, Revathi , Zode, Gulab , Stout, J. Timothy, Li, Yumei

Mayo Clinic

No container title available | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.17.732980 | PMID 42395492 Get It

Abstract The trabecular meshwork (TM) and ciliary body (CB) regulate aqueous humor dynamics and intraocular pressure (IOP), and TM/Schlemm’s canal (SC) dysfunction underlies glaucoma. Here, we present a spatially resolved multi-omics atlas of human TM and CB, integrating snRNA-seq, scRNA-seq, and snATAC-seq from over one million cells and nuclei across 112 donors with Xenium spatial transcriptomics. We identified 9 major cell classes and 21 cell types, revealing heterogeneity, including undercharacterized fibroblast and epithelial subpopulations. Spatial mapping supported TM fibroblast zonation and CB epithelial organization. Regulatory analyses identified cell type–specific programs, including OTX/PAX networks in CB epithelium and SMAD3/TGF-β signaling in fibroblasts. Integration with glaucoma loci showed enrichment of non-coding variants in regulatory elements associated with POAG and PACG. Age- and ancestry-associated remodeling revealed divergent fibroblast aging with increased PIEZO1 , suggesting impaired outflow and elevated IOP. Together, this high-resolution atlas links cellular, regulatory, and genetic variation to anterior segment function and glaucoma susceptibility.
Variation in Chronic Automated Red Cell Exchange Practices for Sickle Cell Disease: Insights Into Isovolemic Hemodilution Use
Jones, Jennifer M. , Aldarweesh, Fatima , Aqui, Nicole, Bobr, Aleh , Brunker, Patricia A. R. , Covington, Mischa L. , Guarente, Juliana , Hagar, Robert, Karafin, Matthew, Lamba, Divjot Singh , Lee, Grace M. , Mack, Ethan A. , Muthur, Gagan, Nazli, Saadiya, Olaniyan, H S, Raval, Jay S., Setya, Divya , Tanhehco, Yvette C. , Thant, Mamie, Wu, Yanyun , Wong, Edward C.C. , Zheng, Yan , Brunker, Patricia A R , Lee, Grace , Lu, Wen , Mack, Ethan A , Onyenekwu, Chinelo P , Setya, Divya , Tanhehco, Yvette C , Vivero, Angelica , Yurtsever, Nalan , Zheng, Yan , Shi, Patricia A , Webb, Jennifer , Aldarweesh, Fatima , Aqui, Nicole A., Hagar, Robert Ward, Lu, Wen , Nazli, Saadiya , Yurtsever, Nalan , Shi, Patricia A.

Mayo Clinic

Journal of Clinical Apheresis | June 19, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70146 | PMID 42316838 Get It

ABSTRACT Prior surveys of chronic automated red blood cell exchange (RCE) for patients with sickle cell disease (SCD) have identified considerable procedural variability, especially with the use of isovolemic hemodilution red blood cell exchange (IHD‐RCE). We conducted a survey of chronic RCE practices among American Society for Apheresis (ASFA) members to identify opportunities for practice harmonization and future studies. The ASFA SCD Research Subcommittee developed a 72‐item survey of chronic RCE practices, with a focus on IHD‐RCE. The survey was validated internally and distributed by email to all ASFA members from September 2024 to February 2025. One survey response from each institution was retained for data analysis. Descriptive statistics were performed. Sixty‐two survey responses, including three from international institutions, were retained for analysis. Sixty‐one percent of respondents (38/62) reported using at least one fixed RCE target, with end hematocrit being the most common fixed parameter (40%, 25/62), followed by fraction of cells remaining (31%, 19/62) and hemoglobin S% (27%, 17/62). Most respondents (60%, 37/61) performed IHD‐RCE at their institution, though other details such as the minimum hematocrit, exclusion criteria, and response to adverse effects were variable. Consistent pre‐ and post‐RCE laboratory monitoring practices were reported. Consistent with earlier surveys, procedural variability in chronic RCE practices for patients with SCD is observed. This highlights opportunities to compare outcomes where practice variability exists. Consensus guidelines based on institutional practices with optimal outcomes should be developed.